Literature DB >> 9869560

Development of rifapentine susceptibility tests for Mycobacterium tuberculosis.

L Heifets1, T Sanchez, J Vanderkolk, V Pham.   

Abstract

Two methods for testing the susceptibility of Mycobacterium tuberculosis to rifapentine have been developed: the agar proportion method and the radiometric BACTEC technique. A critical concentration of 0.5 microg of rifapentine per ml is proposed for both methods since it provides a reliable means of distinguishing between susceptible and resistant M. tuberculosis isolates. It is recommended that two quality control M. tuberculosis strains be used at the introduction of these tests in a clinical laboratory: one that is pansusceptible (H37Rv) and one that is resistant to rifapentine. The resistant strain can be obtained from the American Type Culture Collection, where it is deposited under the number ATCC 700457.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 9869560      PMCID： PMC89015     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosis.

Authors:  J Dhillon; J M Dickinson; J A Guy; T K Ng; D A Mitchison
Journal:  Tuber Lung Dis       Date:  1992-04

2.  [In-vitro antimycobacterial activity of rifapentine (comparison with rifampicin)].

Authors:  M Tsukamura; S Mizuno; H Toyama
Journal:  Kekkaku       Date:  1986-12

3.  Comparison of the sensitivity of mycobacteria to the cyclopentyl rifamycin DL473 and rifampicin.

Authors:  M D Yates; C H Collins
Journal:  J Antimicrob Chemother       Date:  1982-08       Impact factor: 5.790

4.  In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis.

Authors:  J M Dickinson; D A Mitchison
Journal:  Tubercle       Date:  1987-06

5.  Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis.

Authors:  L B Heifets; P J Lindholm-Levy; M A Flory
Journal:  Am Rev Respir Dis       Date:  1990-03

6.  [Activity of intermittently administered rifampicin and cyclopentyl rifamycin (or DL473) on experimental tuberculosis in the mouse].

Authors:  C Truffot-Pernot; J Grosset; R Bismuth; H Lecoeur
Journal:  Rev Fr Mal Respir       Date:  1983

7.  Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages.

Authors:  J Dhillon; D A Mitchison
Journal:  Am Rev Respir Dis       Date:  1992-01

8.  Antibacterial activity of DL 473, a new semisynthetic rifamycin derivative.

Authors:  V Arioli; M Berti; G Carniti; E Randisi; E Rossi; R Scotti
Journal:  J Antibiot (Tokyo)       Date:  1981-08       Impact factor: 2.649

9.  Uptake and activity of rifapentine in human peritoneal macrophages and polymorphonuclear leukocytes.

Authors:  A Pascual; D Tsukayama; J Kovarik; G Gekker; P Peterson
Journal:  Eur J Clin Microbiol       Date:  1987-04       Impact factor: 3.267

10.  Effectiveness of clarithromycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice.

Authors:  B Ji; E G Perani; J H Grosset
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191
View more
  4 in total

1.  Single-dose intrapulmonary pharmacokinetics of rifapentine in normal subjects.

Authors:  J E Conte; J A Golden; M McQuitty; J Kipps; E T Lin; E Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

2.  Rapid detection of rifampin resistance in Mycobacterium tuberculosis isolates by heteroduplex analysis and determination of rifamycin cross-resistance in rifampin-resistant isolates.

Authors:  Zeynep Saribaş; Tanil Kocagöz; Alpaslan Alp; Ayfer Günalp
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

3.  Rapid determination of rifampin resistance in clinical isolates of Mycobacterium tuberculosis by real-time PCR.

Authors:  Tanil Kocagoz; Zeynep Saribas; Alpaslan Alp
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

4.  Chemotherapeutic interventions against tuberculosis.

Authors:  Neeraj Shakya; Gaurav Garg; Babita Agrawal; Rakesh Kumar
Journal:  Pharmaceuticals (Basel)       Date:  2012-06-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.